Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PDSB 
PDS Biotechnology Corp (PDSB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PDSB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.34% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 44.47M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 3 | Beta 1.1 | 52 Weeks Range 0.85 - 3.48 | Updated Date 10/17/2025 |
52 Weeks Range 0.85 - 3.48 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.42% | Return on Equity (TTM) -156.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34629283 | Price to Sales(TTM) - |
Enterprise Value 34629283 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.58 | Shares Outstanding 47025502 | Shares Floating 45233895 |
Shares Outstanding 47025502 | Shares Floating 45233895 | ||
Percent Insiders 3.03 | Percent Institutions 16.57 |
Upturn AI SWOT
PDS Biotechnology Corp
Company Overview
History and Background
PDS Biotechnology Corp is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancer. Founded in 2006, it has evolved from a discovery-stage firm to one conducting clinical trials across multiple cancer indications.
Core Business Areas
- Versamuneu00ae Technology Platform: The core technology platform driving their immuno-oncology drug development efforts, designed to activate and expand antigen-specific T-cells in vivo.
- PDS0101 Program: The lead product candidate in clinical development for HPV-associated cancers, including cervical, anal, head and neck cancers.
- PDS0301 Program: An earlier-stage product candidate targeting multiple solid tumors, including ovarian, breast and colorectal cancer.
Leadership and Structure
Dr. Frank Bedu-Addo serves as the President and CEO. The company has a board of directors and various functional departments including research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- PDS0101: PDS0101 is the company's lead product candidate, an investigational agent designed to activate T-cells to target HPV16-driven cancers. Market share is not yet applicable as the product is still in clinical trials, competing with other immuno-oncology approaches, including Merck's Keytruda and Bristol Myers Squibb's Opdivo in relevant indications.
- Versamuneu00ae Technology: The underlying technology platform aims to improve the efficacy of cancer immunotherapies. As a platform, it doesn't have a direct market share but its potential lies in improving the performance of cancer vaccines and oncolytic viruses; competitors include synthetic TLR agonists such as Dynavax Technologies and therapeutic vaccine platforms such as Gritstone Bio's EDGE platform.
Market Dynamics
Industry Overview
The oncology market is experiencing rapid growth, driven by an aging population, advances in cancer research, and increasing adoption of targeted therapies and immunotherapies. Immunotherapy is a major growth area.
Positioning
PDS Biotechnology aims to improve the efficacy of cancer immunotherapies through its Versamuneu00ae platform. Its competitive advantage lies in its targeted T-cell activation approach.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. PDS Biotechnology is positioning itself to capture a share of this market by developing more effective and targeted immunotherapies for various cancer types. Exact positioning is still early, driven by clinical trial results.
Upturn SWOT Analysis
Strengths
- Novel Versamuneu00ae technology platform
- Strong preclinical and early clinical data
- Experienced leadership team
- Focus on unmet needs in cancer treatment
Weaknesses
- Limited financial resources
- Single product candidate dependence (PDS0101)
- Clinical trial execution risks
- Regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Positive clinical trial results leading to regulatory approval
- Increased adoption of immunotherapy in cancer treatment
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Changes in regulatory landscape
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
Competitive Landscape
PDS Biotechnology is a smaller player compared to major pharmaceutical companies. It needs to leverage its niche in targeted immunotherapy.
Growth Trajectory and Initiatives
Historical Growth: Historically limited revenues but has seen growth in R&D activity and stock value influenced by Phase 2 trial success.
Future Projections: Future growth depends on the success of clinical trials for PDS0101 and other candidates. Analyst estimates vary widely.
Recent Initiatives: Focus on advancing PDS0101 through Phase 3 trials and expanding the pipeline through strategic partnerships.
Summary
PDS Biotechnology is a clinical-stage company with a promising Versamuneu00ae technology, but its financial stability is concerning. Positive trial results and strategic partnerships will be vital for future success. They need to navigate clinical trials, secure financing, and deal with strong competition. The company is in a very risky position, and a lot is riding on their technology delivering the desired outcome.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PDS Biotechnology Corp
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2015-10-01 | President, CEO & Director Dr. Frank K. Bedu-Addo Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.pdsbiotech.com |
Full time employees 24 | Website https://www.pdsbiotech.com | ||
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.